Abratt, RP Brune, D Dimopoulos, MA Kliment, J Breza, J Selvaggi, P Beuzeboc, P Demkow, T Oudard, S, 864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study, EJC supplements, (5), S260, 2003,